BCDT reinfusion based on CD27+ memory B-cells has been adopted by certain groups treating patients with neuromyelitis optica spectrum disorder, myasthenia gravis, as well as patients with MS [11, 16–19]. Here, CD27 is linked to neuromyelitis optica.